A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

计划入组 150 人 · 首次发布于 2022 年 5 月 27 日

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

计划入组 60 人 · 首次发布于 2020 年 11 月 25 日

Jin-shui Huan-xian Granule in the Treatment of IPF

计划入组 312 人 · 首次发布于 2019 年 12 月 5 日

JIN-A03

JIN-002

JIN-2017

KIM JIN HO

Argentina

Rheon Medical SA

Switzerland

LUEN CHEONG HONG

Hong Kong, China

Nanomedicine Pioneer Cheon Jin-woo Named Korea's Top Scientist of 2026 for Magnetogenetics and Neural Circuit Breakthroughs

J INTS BIO's Fourth-Generation EGFR-TKI JIN-A02 Shows Promising Anti-Tumor Activity in Resistant NSCLC Patients

Daewoong's First-in-Class IPF Drug Bersiporocin Clears Third Safety Review, Phase 2 Trial Nears Completion